Related Experiment Video
Updated: Jun 23, 2026
05:39
Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
Published on: October 30, 2018
[Paediatric Expert Group on the Immunization Programme. Activities focusing on effective immunization in Poland]
Anna Dobrzańska1, Ewa Bernatowska, Jacek Wysocki
1Klinika Patologii i Intensywnej Terapii Noworodka, Instytut Pomnik, Centrum Zdrowia Dziecka w Warszawie.
Medycyna Wieku Rozwojowego
|May 8, 2009
Summary
The Paediatric Expert Group on the Immunization Programme was established to unify vaccination policies. This aims to rapidly improve the prevention of serious childhood infectious diseases.
Area of Science:
- Pediatrics
- Public Health
- Immunology
Context:
- Established in January 2007, the Paediatric Expert Group on the Immunization Programme serves as an independent advisory body to the Minister of Health.
- Comprised of pediatricians from diverse sub-specialties, many affiliated with the Polish Society of Vaccinology.
- The group's informal activities began in 2005, with initial projects focusing on tuberculosis immunization and prophylaxis for measles, mumps, and rubella.
Purpose:
- To establish a unified policy for vaccination matters within the national immunization program.
- To drive swift advancements in the prophylaxis of infectious diseases posing risks to children's health and lives.
Summary:
- The Paediatric Expert Group on the Immunization Programme, formed in 2007, comprises pediatric specialists.
- This independent advisory body collaborates with health authorities and research institutes.
- Key initiatives include updating immunization schedules for diseases like tuberculosis, measles, mumps, and rubella.
Impact:
- Facilitates rapid implementation of updated vaccination strategies.
- Enhances the protection of children against preventable infectious diseases.
- Contributes to a cohesive national approach to pediatric immunization programs.
Related Concept Videos
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:51Vaccinations
Overview